NovaQuest Private Equity Acquires CoreRx, Inc.

CoreRx Acquires Nucleo Life Sciences

May 24, 2021

Pharmaceuticals

CoreRx, Inc. has acquired Nucleo Life Sciences, a boutique CDMO based in San Rafael, California, expanding CoreRx’s US West Coast development presence and formulation capabilities. The deal, supported by CoreRx’s majority owner NovaQuest Private Equity and other shareholders, will integrate Nucleo’s Fast-to-Clinic formulation expertise (including spray-dried dispersions and NucleLoad) into CoreRx’s development and manufacturing platform.

CoreRx, Inc. Acquires Societal CDMO, Inc.

April 8, 2024

Pharmaceuticals

CoreRx, Inc. completed its acquisition of Societal CDMO, Inc. through a tender offer and subsequent short-form merger, acquiring approximately 92.8% of outstanding shares at $1.10 per share. Societal CDMO is now a wholly owned subsidiary of CoreRx and its common stock will be delisted from the Nasdaq Capital Market.

ARCHIMED and CDPQ Recapitalize Corealis Pharma

May 24, 2022

Pharmaceuticals

Transatlantic PE firm ARCHIMED, joined by Caisse de dépôt et placement du Québec (CDPQ), has recapitalized Corealis Pharma, a Laval, Quebec–based CDMO specializing in oral solid dosage formulation and clinical-supply manufacturing. The recapitalization will fund expansion of GMP-compliant facilities, R&D capabilities and accelerate growth for Corealis to serve small- and mid-sized biotech and pharma customers.

Bend Bioscience Unites CoreRx and Societal CDMO Under Single Bend Bioscience Brand

September 4, 2024

Pharmaceuticals

Bend Bioscience has unified CoreRx and Societal CDMO under the Bend Bioscience brand to form an integrated contract development and manufacturing organization (CDMO). The consolidation combines CoreRx’s formulation development expertise, Societal CDMO’s scalable cGMP manufacturing and packaging capabilities, and Bend Bioscience’s research and technology to offer end-to-end development-to-commercialization services across facilities in Bend, Oregon; Clearwater, Florida; and Gainesville, Georgia.

PharmaCorp Rx Inc. Acquires Pharmacy in Atlantic Canada

October 2, 2024

Healthcare Services

PharmaCorp Rx Inc. (TSXV: PCRX) completed the acquisition of a 100% interest in a pharmacy business, including the associated land and buildings, located in Atlantic Canada for an aggregate purchase price of $15,377,013. The transaction was financed with $15,177,013 in cash and $200,000 in common shares and expands PharmaCorp’s roll-up of independent PharmaChoice Canada-affiliated pharmacies.

LGM Pharma Acquires Nexgen Pharma's Drug Product CDMO Business

July 23, 2020

Pharmaceuticals

LGM Pharma has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, expanding LGM's CDMO capabilities and U.S.-based manufacturing footprint. Financial support for the transaction was provided by private equity firm New Harbor Capital; Nexgen Pharma sold its pharmaceutical CDMO unit to allow the company to focus on other healthcare segments.